相似文献
1
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Clin Neurol Neurosurg. 2020 Oct;197:106203. doi: 10.1016/j.clineuro.2020.106203. Epub 2020 Sep 2.
2
COVID-19 will change MS care forever - No.
Mult Scler. 2020 Sep;26(10):1149-1151. doi: 10.1177/1352458520929971. Epub 2020 Jun 22.
3
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
4
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12.
5
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Mult Scler Relat Disord. 2020 Aug;43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.
6
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
CNS Drugs. 2021 Mar;35(3):317-330. doi: 10.1007/s40263-021-00804-1. Epub 2021 Mar 20.
7
Novel Agents for Relapsing Forms of Multiple Sclerosis.
Annu Rev Med. 2016;67:309-21. doi: 10.1146/annurev-med-052814-023415. Epub 2015 Sep 17.
8
Effector and regulatory B cells in Multiple Sclerosis.
Clin Immunol. 2017 Nov;184:11-25. doi: 10.1016/j.clim.2017.04.014. Epub 2017 Apr 28.
9
Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Medicina (Kaunas). 2020 Jan 21;56(2):49. doi: 10.3390/medicina56020049.
10
Update on disease-modifying therapies for multiple sclerosis.
J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27.
引用本文的文献
1
Multiple sclerosis and COVID-19: a northern China survey.
Neurol Sci. 2024 Aug;45(8):3563-3571. doi: 10.1007/s10072-024-07578-6. Epub 2024 May 9.
2
Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia.
Mult Scler Relat Disord. 2021 Jul;52:103004. doi: 10.1016/j.msard.2021.103004. Epub 2021 May 7.
3
Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
Neurol Ther. 2021 Dec;10(2):435-454. doi: 10.1007/s40120-021-00243-6. Epub 2021 Apr 23.
4
Rituximab for the treatment of multiple sclerosis: a review.
J Neurol. 2022 Jan;269(1):159-183. doi: 10.1007/s00415-020-10362-z. Epub 2021 Jan 8.
本文引用的文献
1
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
2
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Mult Scler Relat Disord. 2020 Jul;42:102182. doi: 10.1016/j.msard.2020.102182. Epub 2020 May 8.
3
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
4
Type 1 interferons as a potential treatment against COVID-19.
Antiviral Res. 2020 Jun;178:104791. doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.
Zotero 插件